semaglutide weight loss mechanism Semaglutide-Mediated Remodeling of Adipose Tissue in Type 2 Diabetes: Molecular Mechanisms Beyond Glycemic Control Beyond GLP-1: Retatrutide's triple-agonist mechanism

Starting Dose: 2.5 mg SC every week for 4 weeks initially

Because of this, retatrutide is thought to be more effective than Wegovy, which only binds to GLP-1 receptors, and Mounjaro, which is a dual agonist that mimics the effects of GLP-1 and GIP

further splitting adds little High efficacy retention: Even daily microdosing maintains ~85% theoretical efficacy Long half-life advantage: Semaglutide's natural stability means less benefit from splitting vs

It is not currently covered by public health insurance (as of early 2025)

Starting our patients with semaglutide also allows us to evaluate how they respond to GLP-1 therapy alone before potentially introducing the additional GIP action with tirzepatide